J. Thompson

发表

Characterisation of targeted imaging and theranostic agents for cancer and fibrosis

J. Thompson, 2018 .

MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.

M. Lotem, B. Ksander, S. Ostrand-Rosenberg, 2007, Cancer research.

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

B. Fox, T. Crocenzi, W. Urba, 2009, Current molecular medicine.

AWARD NUMBER: DAMD17-03-1-0337 TITLE: Novel MHC Class II Breast Cancer Vaccine Using RNA Interference (RNAi) to Down Regulate Invariant Chain (Ii)

J. Thompson, 2006 .

Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines

Peter W. Chen, B. Ksander, S. Ostrand-Rosenberg, 2004, Cancer Research.

64Cu PET Imaging of the CXCR4 Chemokine Receptor Using a Cross-Bridged Cyclam Bis-Tetraazamacrocyclic Antagonist

D. Schols, T. Ruest, C. Cawthorne, 2020, The Journal of Nuclear Medicine.

Invariant Chain and CLIP down-modulation enhances immunogenicity of leukemic blasts resulting in increased CD 4 + T cell responses

M. M. Luijn, J. Thompson, M. Chamuleau, 2011 .

The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes

B. Ksander, S. Ostrand-Rosenberg, Suzanne Ostrand-Rosenberg, 2008, Cancer Immunology, Immunotherapy.

Novel MHC Class II Breast Cancer Vaccine Using RNA Interference (RNAi) to Down Regulate Invariant Chain (Ii)

J. Thompson, 2007 .

Autologous Regulatory T Cells for the Treatment of Type 1 Diabetes

D. Perry, T. Brusko, J. Thompson, 2012, Current Diabetes Reports.

Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.

B. Ksander, K. Knutson, M. Disis, 2006, Cancer research.

Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

M. Edelman, B. Ksander, S. Ostrand-Rosenberg, 2008, Cancer Immunology, Immunotherapy.

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses

J. Thompson, G. Ossenkoppele, A. A. van de Loosdrecht, 2010, Haematologica.

Protease nexins: Cell‐secreted proteins that mediate the binding, internalization, and degradation of regulatory serine proteases

J. Thompson, J. Thompson, D. Knauer, 1983, Journal of cellular physiology.